Other Publications Referenced in Amarin’s Investor Communications
The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites.
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Wong ND, Toth PP, Amsterdam EA, on behalf of theAmerican Society for Preventive Cardiology, Most Important Advances in Preventive Cardiology During this Past Decade: Viewpoint from the American Society for Preventive Cardiology, Trends in Cardiovascular Medicine (2019)
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.